Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

719
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
719
Tissue Transplantation01:24

Tissue Transplantation

1.2K
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
1.2K
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

815
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
815
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

2.5K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
2.5K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

86.6K
Overview
86.6K
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

580
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
580

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Case Report: Haemopoietic stem cell transplantation in refractory paediatric RAS-associated lymphoproliferative disorder.

Frontiers in immunology·2026
Same author

Targeting the cytokine storm: new therapies in the treatment of pediatric hemophagocytic lymphohistiocytosis.

Expert review of clinical immunology·2026
Same author

RNA activation as a precision dosing modality: MTL-CEBPA for controlled enzyme elevation in MPS I-H.

Frontiers in medicine·2026
Same author

The impact of pre-transplant extramedullary disease on the outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukaemia in children- on behalf of PDWP/EBMT.

Bone marrow transplantation·2026
Same author

Don't Cut the Cord: Why Umbilical Cord Blood Still Deserves a Place in Transplantation.

International journal of immunogenetics·2026
Same author

Outcome of second conditioned allogeneic stem cell transplant in children with non-SCID inborn errors of immunity.

Blood advances·2026
Same journal

Hyperlactataemia in lymphoma-associated haemophagocytic lymphohistiocytosis: Linked to monocytic glycolysis and adverse prognosis.

British journal of haematology·2026
Same journal

Clinical outcomes of the chemo-free approach in relapsed/refractory follicular lymphoma: A network meta-analysis.

British journal of haematology·2026
Same journal

Early venetoclax dose escalation at minimal residual disease progression may benefit selected acute myeloid leukaemia patients.

British journal of haematology·2026
Same journal

Evaluating high-sensitivity troponin levels in people with sickle cell disease in the emergency department.

British journal of haematology·2026
Same journal

Methaemoglobinaemia: From pathophysiology to contemporary clinical management.

British journal of haematology·2026
Same journal

Effects of chronic lymphocytic leukaemia (CLL)-directed therapy on diffuse large B-cell lymphoma (DLBCL) type Richter transformation compared to de novo DLBCL in a nationwide cohort.

British journal of haematology·2026
See all related articles

Related Experiment Video

Updated: Apr 7, 2026

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

16.8K

Serotherapy in transplant: Getting it right!

Robert Wynn1, Rick Admiraal2, Caroline Lindemans2

  • 1Blood and Marrow Transplant Programme, Royal Manchester Children's Hospital, Manchester, UK.

British Journal of Haematology
|April 6, 2026
PubMed
Summary
This summary is machine-generated.

Dose de-escalation of alemtuzumab may be a viable strategy in matched unrelated donor hematopoietic stem cell transplantation, potentially improving outcomes. This approach warrants further investigation in clinical practice.

Keywords:
graft versus host Diseaseserotherapytransplant

More Related Videos

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

15.0K
Orthotopic Rat Kidney Transplantation: A Novel and Simplified Surgical Approach
09:15

Orthotopic Rat Kidney Transplantation: A Novel and Simplified Surgical Approach

Published on: May 7, 2019

17.3K

Related Experiment Videos

Last Updated: Apr 7, 2026

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

16.8K
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

15.0K
Orthotopic Rat Kidney Transplantation: A Novel and Simplified Surgical Approach
09:15

Orthotopic Rat Kidney Transplantation: A Novel and Simplified Surgical Approach

Published on: May 7, 2019

17.3K

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Hematopoietic stem cell transplantation (HSCT) is a crucial treatment for hematologic malignancies.
  • Alemtuzumab is an effective antibody for T-cell depletion in HSCT but can cause significant toxicity.
  • Optimizing alemtuzumab dosing is essential for balancing efficacy and safety.

Purpose of the Study:

  • To evaluate the feasibility and outcomes of a reduced-dose alemtuzumab regimen.
  • To assess the impact of dose de-escalation on graft-versus-host disease (GVHD) and graft rejection.
  • To explore the safety profile of de-escalated alemtuzumab in matched unrelated donor HSCT.

Main Methods:

  • Retrospective analysis of patients undergoing matched unrelated donor HSCT.
  • Comparison of outcomes between standard-dose and de-escalated alemtuzumab groups.
  • Assessment of engraftment, GVHD incidence, and overall survival.

Main Results:

  • The commentary discusses a study on alemtuzumab dose de-escalation.
  • Matched unrelated donor HSCT outcomes were analyzed in relation to alemtuzumab dosing.
  • Preliminary findings suggest potential for reduced toxicity with de-escalated doses.

Conclusions:

  • Dose de-escalation of alemtuzumab is a potential strategy in matched unrelated donor HSCT.
  • Further research is needed to confirm safety and efficacy.
  • This approach may improve the risk-benefit ratio of alemtuzumab in transplantation.